By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Epeius Biotechnologies Corporation 

475 Huntington Drive

San Marino  California  91108  U.S.A.
Phone: 626-441-6695 Fax: 626-441-6692


Epeius is a biopharmaceutical company formed to develop and commercialize a targeted delivery system (TDS) that can be injected directly into a vein to deliver genes or other biomolecules to cancerous tumors, without creating side effects or organ damage. Targeted therapeutics in general are more effective and less toxic than conventional medicines, and targeted gene delivery in particular, long considered to be the "holy grail" of gene therapy, represents a major medical need. The company's Rexin-GTM product is the first tumor-targeted injectable gene therapy vector (i.e. a targeted nanoparticle) to be approved by the U.S. FDA and the Philippine BFAD (FDA counterpart) for use in Phase I/II and Phase II/III clinical trials and has been demonstrated to cause shrinkage and necrosis of primary and metastatic cancers in humans. Rexin-G has also recently been granted orphan drug status in the U.S. for treatment of pancreatic cancer, which gives the company market exclusivity for the Rexin-G product for all types of pancreatic cancer.

Key Statistics

Ownership: Private

Web Site: Epeius Biotechnologies

Company News
Epeius Biotechnologies Corporation's REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA 3/1/2011 7:39:21 AM
Epeius Biotechnologies Corporation Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy 11/8/2010 11:09:34 AM
Epeius Biotechnologies Corporation Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma 6/1/2010 11:56:36 AM
Epeius Biotechnologies Corporation: Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies 5/25/2010 8:34:24 AM
Epeius Biotechnologies Corporation: Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer 5/25/2010 8:01:10 AM
Epeius Biotechnologies Corporation Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy 5/5/2010 9:05:20 AM
Epeius Biotechnologies Corporation Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines 3/16/2010 8:59:45 AM
Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California 2/19/2010 7:52:30 AM
Epeius Biotechnologies Corporation: Scientists Rediscover Gene Target for Cancer Therapy Rexin-G Receives High-tech Validation as Strategic Anti-cancer Agent 12/15/2009 12:11:01 PM
Epeius Biotechnologies Corporation to Partner at Biotechnology Industry Organization (BIO) Investor Forum Tumor-targeted Rexin-G is Showcased as a Leading Candidate and Investment Opportunity 10/21/2009 8:46:56 AM